Market Cap 48.05B
Revenue (ttm) 30.24B
Net Income (ttm) 712.32M
EPS (ttm) N/A
PE Ratio 9.68
Forward PE 9.09
Profit Margin 2.36%
Debt to Equity Ratio 0.65
Volume 1,261,638
Avg Vol 2,950,682
Day's Range N/A - N/A
Shares Out 3.18B
Stochastic %K 93%
Beta 0.03
Analysts Sell
Price Target $18.10

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 81 3 3278-2111
Fax: 81 3 3278-2000
Address:
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
Quantumup
Quantumup Dec. 22 at 11:32 AM
a/o Friday: BMO Capital reiterated $IRON Outperform/$120 Jefferies reiterated Buy/$154 TD Cowen reiterated Buy Stifel analyst reiterated Buy/$125 $CLVLY Mitsubishi Tanabe Pharma $NVS ABBV GERN $PTGX - $TAK Here's what the Analysts had to say on Friday:
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 22 at 3:21 AM
$ALMS $TAK https://www.biopharmadive.com/news/takeda-zasocitinib-tyk2-psoriasis-drug-results-nimbus/808237/ Alms is worth $4B There's your low end mc target. 💪😎
0 · Reply
Rajesh100
Rajesh100 Dec. 18 at 10:14 PM
$ALMS $TAK https://stocks.apple.com/Awcjft6ItSa624Pw0bbALeA
0 · Reply
briefingcom
briefingcom Dec. 18 at 1:46 PM
$TAK: Takeda’s Zasocitinib Landmark Phase 3 plaque psoriasis data show promise to deliver clear skin in a once-daily pill, catalyzing a new era of treatment
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:49 PM
Citizens reiterated $PTGX Market Outperform/$102. $TAK $JNJ Citizens said in its note: PTGX has a big decision coming up by mid-2026 when management has to determine whether to opt out of its 50/50 U.S. profit/loss share for rusfertide with Takeda, which would change PTGX's downstream economics. We assume PTGX will opt out to bring in more risk-free cash that the company can deploy to advance its earlier-stage internal pipeline.
0 · Reply
wyoming2020
wyoming2020 Dec. 11 at 11:18 AM
$PDSB might get some interest in Japan with patent $TAK a potential partner there / big multinational with interesting oncology pipeline
3 · Reply
Quantumup
Quantumup Dec. 10 at 2:04 PM
H.C. Wainwright y'day⬆️ $IMMX's PT to $12 from $8, plus⬆️PoS to 85% and reiterated at a Buy rating. $PRTA $AZN $JNJ ABBV $TAK BMY SNY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/1998754299422122357?s=20
0 · Reply
prismmarketview
prismmarketview Dec. 8 at 4:33 PM
Protagonist Therapeutics’(NASDAQ: $PTGX) and Takeda (NYSE: $TAK), Rusfertide continues to impress in PV, with Phase 3 VERIFY data showing durable 52-week hematocrit control, a double-digit fold reduction in annual phlebotomy rates, and sustained responses that strengthen its first-in-class profile. https://prismmarketview.com/protagonist-therapeuticss-rusfertide-delivers-durable-results-in-phase-iii/
0 · Reply
SparkyReturns
SparkyReturns Dec. 8 at 4:33 PM
$BIIB I'm surprised some of the large drug companies haven't noticed what ICU is doing.... Check out this investing idea. * ICU * What other company has a market cap of only $12 Million but is launching a product with an annual market in the 10s of BILLIONS? [Read that again = 1000x] Patients' lives are saved and eliminates $100K/ year of dialysis dependency; Device has broad application for over a half dozen critical conditions (kidney, heart, ARDS, Sepsis, Covid, burns, etc); The device "sells itself" by saving hospitals $40K per average stay; Insurers will love it because their costs will go down; Government will love it to reduce number of Medicare patients on lifetime dialysis; FDA seems to be fast tracking all decisions, already gave grants; ZERO DEBT, and revenue ramping up. This may be the best time to get in to ICU for those looking for an investing idea. Cheers! $SNY $TAK $RDY $TEVA
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 7 at 11:34 PM
$PTGX $TAK Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera "52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary Endpoints"
0 · Reply
Latest News on TAK
US FDA investigates death tied to Takeda's blood disorder drug

Nov 21, 2025, 12:00 PM EST - 4 weeks ago

US FDA investigates death tied to Takeda's blood disorder drug


Takeda Pharmaceutical to exit cell therapy research

Oct 1, 2025, 9:41 AM EDT - 3 months ago

Takeda Pharmaceutical to exit cell therapy research


Shares of Asian drugmakers drop after Trump threatens tariffs

Sep 25, 2025, 10:52 PM EDT - 3 months ago

Shares of Asian drugmakers drop after Trump threatens tariffs


What's Going On With Takeda Stock On Friday?

Aug 22, 2025, 11:21 AM EDT - 4 months ago

What's Going On With Takeda Stock On Friday?


Takeda Announces New Assignments of Directors

Jun 25, 2025, 3:07 AM EDT - 6 months ago

Takeda Announces New Assignments of Directors


Quantumup
Quantumup Dec. 22 at 11:32 AM
a/o Friday: BMO Capital reiterated $IRON Outperform/$120 Jefferies reiterated Buy/$154 TD Cowen reiterated Buy Stifel analyst reiterated Buy/$125 $CLVLY Mitsubishi Tanabe Pharma $NVS ABBV GERN $PTGX - $TAK Here's what the Analysts had to say on Friday:
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 22 at 3:21 AM
$ALMS $TAK https://www.biopharmadive.com/news/takeda-zasocitinib-tyk2-psoriasis-drug-results-nimbus/808237/ Alms is worth $4B There's your low end mc target. 💪😎
0 · Reply
Rajesh100
Rajesh100 Dec. 18 at 10:14 PM
$ALMS $TAK https://stocks.apple.com/Awcjft6ItSa624Pw0bbALeA
0 · Reply
briefingcom
briefingcom Dec. 18 at 1:46 PM
$TAK: Takeda’s Zasocitinib Landmark Phase 3 plaque psoriasis data show promise to deliver clear skin in a once-daily pill, catalyzing a new era of treatment
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:49 PM
Citizens reiterated $PTGX Market Outperform/$102. $TAK $JNJ Citizens said in its note: PTGX has a big decision coming up by mid-2026 when management has to determine whether to opt out of its 50/50 U.S. profit/loss share for rusfertide with Takeda, which would change PTGX's downstream economics. We assume PTGX will opt out to bring in more risk-free cash that the company can deploy to advance its earlier-stage internal pipeline.
0 · Reply
wyoming2020
wyoming2020 Dec. 11 at 11:18 AM
$PDSB might get some interest in Japan with patent $TAK a potential partner there / big multinational with interesting oncology pipeline
3 · Reply
Quantumup
Quantumup Dec. 10 at 2:04 PM
H.C. Wainwright y'day⬆️ $IMMX's PT to $12 from $8, plus⬆️PoS to 85% and reiterated at a Buy rating. $PRTA $AZN $JNJ ABBV $TAK BMY SNY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/1998754299422122357?s=20
0 · Reply
prismmarketview
prismmarketview Dec. 8 at 4:33 PM
Protagonist Therapeutics’(NASDAQ: $PTGX) and Takeda (NYSE: $TAK), Rusfertide continues to impress in PV, with Phase 3 VERIFY data showing durable 52-week hematocrit control, a double-digit fold reduction in annual phlebotomy rates, and sustained responses that strengthen its first-in-class profile. https://prismmarketview.com/protagonist-therapeuticss-rusfertide-delivers-durable-results-in-phase-iii/
0 · Reply
SparkyReturns
SparkyReturns Dec. 8 at 4:33 PM
$BIIB I'm surprised some of the large drug companies haven't noticed what ICU is doing.... Check out this investing idea. * ICU * What other company has a market cap of only $12 Million but is launching a product with an annual market in the 10s of BILLIONS? [Read that again = 1000x] Patients' lives are saved and eliminates $100K/ year of dialysis dependency; Device has broad application for over a half dozen critical conditions (kidney, heart, ARDS, Sepsis, Covid, burns, etc); The device "sells itself" by saving hospitals $40K per average stay; Insurers will love it because their costs will go down; Government will love it to reduce number of Medicare patients on lifetime dialysis; FDA seems to be fast tracking all decisions, already gave grants; ZERO DEBT, and revenue ramping up. This may be the best time to get in to ICU for those looking for an investing idea. Cheers! $SNY $TAK $RDY $TEVA
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 7 at 11:34 PM
$PTGX $TAK Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera "52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary Endpoints"
0 · Reply
briefingcom
briefingcom Dec. 5 at 1:48 PM
$TAK: Takeda Pharma and Innovent finalize global oncology partnership for IO and ADC pipeline https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251205043300TAK&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Quantumup
Quantumup Dec. 4 at 4:55 PM
Goldman Sachs🏁 $ORIC at an Early-Stage Biotech Designation. $PFE $JNJ $TAK $OTSKY CGEM Here's what Goldman Sachs said in its note: https://x.com/Quantumup1/status/1996623081482162218?s=20
0 · Reply
Quantumup
Quantumup Dec. 3 at 1:45 PM
TD Cowen Named $IONS a 2026 Best Idea, reiterated at a Buy, a $99 PT and said, Best Ideas 2026: New Launches And Key Pipeline Catalysts To Drive Upside $ARWR $TAK BCRX NVS $RHHBY - $PTCT TD Cowen added, We see robust sales growth in FY26 driven by Tryngolza in sHTG, Dawnzera in HAE, zilganersen in AxD, and incremental Spinraza growth. Key Ph3 data in '26 include Wainua in TTR-CM (H2) & pelacarsen in Lp(a) (H1). We see upside from overlooked catalysts: Ph3 bepi in HBV (H1), Ph2 BIIB080 in AD (mid-'26). RARE's GTX-102 Ph3 in Angelman (H2) should clarify ION582's future in this multi-$ B market.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 1 at 7:54 PM
$TAK Current Stock Price: $14.48 Contracts to trade: $15 TAK Dec 19 2025 Call Entry: $0.10 Exit: $0.13 ROI: 29% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Quantumup
Quantumup Dec. 1 at 1:25 PM
B.Riley⬆️ $CNTA's PT to $42 from $33 and reiterated at a Buy rating after Data Deep Dive $ALKS $TAK $AVDL $ESALY HRMY Here's what B.Riley had to say:
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 28 at 11:39 AM
$TAK Share Price: $14.52 Contract Selected: Jul 17, 2026 $15 Calls Buy Zone: $0.63 – $0.78 Target Zone: $1.14 – $1.39 Potential Upside: 69% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Austero
Austero Nov. 25 at 6:18 PM
1 · Reply
SuperGreenToday
SuperGreenToday Nov. 25 at 2:24 PM
$TAK Share Price: $14.22 Contract Selected: Apr 17, 2026 $15 Calls Buy Zone: $0.15 – $0.19 Target Zone: $0.24 – $0.30 Potential Upside: 51% ROI Time to Expiration: 142 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
mikesterz7
mikesterz7 Nov. 21 at 10:55 PM
$TAK The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said.
0 · Reply
prismmarketview
prismmarketview Nov. 21 at 9:06 PM
FDA is investigating Takeda’s (NYSE: $TAK) Adzynma after a pediatric cTTP patient died and developed neutralizing antibodies ~10 months into treatment. Regulators say similar post-marketing reports have emerged, despite no antibody cases in trials, and are now evaluating potential life-threatening risks. https://prismmarketview.com/fda-investigates-takedas-adzynma-after-pediatric-cttp-patient-dies-neutralizing-antibodies-under-review/
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 21 at 4:30 PM
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 21 at 2:41 PM
Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies $TAK $DFAX $JSTC https://stocktwits.com/news/equity/markets/takeda-pharmaceuticals-genetic-disease-therapy-under-fda-probe-after-pediatric-patient-dies/cLPMqISREO8
0 · Reply